The Protective Effect of Prostaglandin on Coronary Microcirculation and Ventricular Remodeling After Reperfusion Therapy in Acute ST-segment Elevation Myocardial Infarction

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 220 participants.

Also called NCT05043558

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 220 participants (planned count) (from the registry)
Sponsor
Shenzhen People's Hospital (from the registry)
Registry
  • NCT NCT05043558
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05043558. Randomized; single masking; primary purpose treatment. Start 2022-01-01 (anticipated); primary completion 2022-01-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Protective Effect of Prostaglandin on Coronary Microcirculation and Ventricular Remodeling After Reperfusion Therapy in Acute ST-segment Elevation Myocardial Infarction
Condition
STEMI
Intervention (Drug)
beprostaglandin sodium
Lead sponsor
Shenzhen People's Hospital (class: other)

Record details

Record id
cardio:ct-nct05043558
Content hash
ce755c9ecabaa059556f83c4a08f991f7a66e711e5688cc5ada9b837eef47bff